Solid Biosciences to Participate at The Citizens Life Sciences Conference
Solid Biosciences (Nasdaq: SLDB), a life sciences company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has announced its upcoming participation in The Citizens Life Sciences Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Solid Biosciences (Nasdaq: SLDB), a life sciences company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has announced its upcoming participation in The Citizens Life Sciences Conference.
The company's President and CEO, Bo Cumbo, will engage in a fireside chat scheduled for Wednesday, May 7, at 12:30 pm ET. Interested parties can access the presentation through a live webcast available on the Events page of the company's Investors section website.
Key Details:
- Event: The Citizens Life Sciences Conference
- Format: Fireside Chat
- Date & Time: May 7, 12:30 pm ET
- Replay Availability: 30-day archive access
Institutional investors seeking management meetings during the conference are advised to contact their Citizens representative.
Positive
- CEO participation in a major life sciences conference indicates strong institutional visibility
Negative
- None.
Details
News Market Reaction – SLDB
The recorded move for SLDB in the trading session of this news was +8.52%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHARLESTOWN, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, announced that Bo Cumbo, President and CEO, will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7, at 12:30 pm ET.
A live webcast of the fireside chat will be available on the Events page of the Investors section of the Company website or by clicking here. The webcast replay will be archived for 30 days on the Events page.
Institutional investors interested in meeting with management during the conference may reach out to their Citizens representative.
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy (Duchenne), Friedreich’s ataxia (FA), catecholaminergic polymorphic ventricular tachycardia (CPVT), TNNT2-mediated dilated cardiomyopathy, BAG3-mediated dilated cardiomyopathy, and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.